Neogen (NEOG) Financials

Neogen’s financial results show a mixed recovery from the substantial impairment-driven losses recorded in fiscal 2025. Revenue has remained relatively stable, while gross margins have improved from the depressed levels seen in fiscal 2025. However, the company remains unprofitable on a quarterly basis, largely because operating expenses and interest costs continue to consume most of its gross profit.

• Revenue remains resilient. Fourth-quarter fiscal 2026 revenue was $225.3 million, nearly flat with $225.5 million in the year-ago quarter and above the $209.2 million reported in fiscal Q1 2026. This suggests the business has maintained a relatively stable sales base despite recent operating challenges.
• Gross margin improved meaningfully. Fourth-quarter gross profit was $107.8 million, equal to a margin of approximately 47.9%, compared with 41.2% in Q4 fiscal 2025. The improvement reflects lower cost of revenue and is a favorable sign for future earnings if sustained.
• Operating performance improved from the impairment-affected period. Neogen reported operating income of $3.2 million in Q4 fiscal 2026, compared with an operating loss of $611.2 million in Q4 fiscal 2025. The year-ago period included a $461.4 million impairment charge, so the comparison is helped by a much lower level of one-time charges.
• Operating cash flow has been consistently positive in fiscal 2026. Cash flow from operations increased from $10.9 million in Q1 to $19.4 million in Q2, $22.7 million in Q3 and $30.2 million in Q4. This provides liquidity even though reported net income remained negative in the final three quarters.
• Cash balances have been rebuilding. Reported cash increased from $138.9 million at the end of Q1 fiscal 2026 to $159.9 million at the end of Q3. The Q4 cash flow statement showed a further $25.6 million increase in cash, which would imply approximately $185.5 million before any balance-sheet reclassification.
• Liquidity appears adequate in the near term. At the end of Q3 fiscal 2026, Neogen had $590.0 million of current assets versus $150.6 million of current liabilities, producing a current ratio of roughly 3.9. The company also reported no short-term debt.
• Capital spending has moderated. Quarterly purchases of property, plant and equipment declined from $24.0 million in Q1 fiscal 2026 to $4.0 million in Q4. This supports near-term free cash flow, although lower investment could limit future growth if the reduction reflects delayed spending rather than improved efficiency.
• The first-quarter profit was not representative of recurring operations. Q1 fiscal 2026 net income of $36.3 million was supported by $75.4 million of other income and $121.7 million of divestiture proceeds in the cash flow statement. Subsequent quarters returned to net losses, making the Q1 result a poor indicator of ongoing earnings power.
• Neogen remains unprofitable. Net losses were $15.9 million in Q2, $17.0 million in Q3 and $11.3 million in Q4 fiscal 2026. Fourth-quarter earnings per share were negative $0.06, following negative EPS of $0.07 and $0.08 in the prior two quarters.
• Interest expense and the company’s intangible-heavy balance sheet remain important risks. Fiscal Q4 interest expense was $12.4 million, while long-term debt stood at $793.3 million at the end of Q3. Goodwill and intangible assets totaled approximately $2.4 billion, or about 71% of total assets, leaving shareholders exposed to future impairment charges if acquired businesses underperform.

Overall, Neogen’s operating trend is improving but not yet fully repaired. Stable revenue, stronger gross margins and rising operating cash flow are encouraging. However, recurring net losses, substantial interest costs and a balance sheet dominated by acquisition-related goodwill and intangible assets mean investors should focus on whether the company can convert its improved gross margin into sustainable operating profit without relying on divestitures or other nonrecurring items.